These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6216987)

  • 1. Medroxyprogesterone acetate (MAP) plasma levels after simultaneous oral and intramuscular administration in cancer patients.
    Pannuti F; Camaggi CM; Strocchi E; Giovannini M; Canova N; Murari G
    Cancer Chemother Pharmacol; 1982; 9(2):122-3. PubMed ID: 6216987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients.
    Camaggi CM; Strocchi E; Giovannini M; Angelelli B; Costanti B; Zebini E; Ferrari P; Pannuti F
    Cancer Chemother Pharmacol; 1983; 11(1):19-22. PubMed ID: 6224604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medroxyprogesterone acetate bioavailability after high-dose intraperitoneal administration in advanced cancer.
    Camaggi CM; Strocchi E; Costanti B; Beghelli P; Ferrari P; Pannuti F
    Cancer Chemother Pharmacol; 1985; 14(3):232-4. PubMed ID: 3158449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of medroxyprogesterone acetate administered by oral and intramuscular routes.
    Salimtschik M; Mouridsen HT; Loeber J; Johansson E
    Cancer Chemother Pharmacol; 1980; 4(4):267-9. PubMed ID: 7438329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients.
    Pannuti F; Camaggi CM; Strocchi E; Giovannini M; Di Marco AR; Costanti B
    Cancer Treat Rep; 1982 Dec; 66(12):2043-9. PubMed ID: 7139647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.
    Camaggi CM; Strocchi E; Canova N; Costanti B; Pannuti F
    Cancer Chemother Pharmacol; 1985; 14(3):229-31. PubMed ID: 3158448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medroxyprogesterone acetate plasma levels after a single oral administration of two drug formulations.
    Pannuti F; Strocchi E; Longhi A; Comparsi R; Camaggi CM
    Chemioterapia; 1986 Aug; 5(4):237-9. PubMed ID: 2945648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic approach to the selection of dose schedules for medroxyprogesterone acetate in clinical oncology.
    Tamassia V; Battaglia A; Ganzina F; Isetta AM; Sacchetti G; Cavalli F; Goldhirsch A; Brunner K; Bernardo G; Robustelli della Cuna G
    Cancer Chemother Pharmacol; 1982; 8(2):151-6. PubMed ID: 6213319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral high-dose medroxyprogesterone acetate (MAP) in treatment of advanced breast cancer. A preliminary report of clinical and experimental studies.
    Izuo M; Iino Y; Endo K
    Breast Cancer Res Treat; 1981; 1(2):125-30. PubMed ID: 6216931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
    Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
    Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
    Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
    Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The plasma concentration of medroxyprogesterone acetate and ovarian function during treatment with medroxyprogesterone acetate in 5 and 10 mg doses.
    Wikström A; Green B; Johansson ED
    Acta Obstet Gynecol Scand; 1984; 63(2):163-8. PubMed ID: 6233840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MPA at high doses in advanced breast cancer: a statistical evaluation.
    Pannuti F; Camaggi CM; Strocchi E; Martoni A
    Chemioterapia; 1986 Jun; 5(3):159-63. PubMed ID: 2941172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous serum testosterone in males after different doses and routes of administration of medroxyprogesterone acetate.
    Novak E; Hendrix JW; Seckman CE; Kaiser DG; Stoll RG
    J Reprod Med; 1980 Oct; 25(4):157-60. PubMed ID: 7431362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology.
    Paridaens R; Becquart D; Michel J; Vanderlinden B; Longueville J; Majois F; Beauduin M; Focan C; Wildiers J; Bernheim J
    Anticancer Res; 1986; 6(5):1089-94. PubMed ID: 2948441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioimmunoassay of 6 alpha-methyl-17 alpha-acetoxyprogesterone (MAP) in plasma of sheep during and after oral administration.
    Sletholt K
    Acta Endocrinol (Copenh); 1981 Jan; 96(1):141-4. PubMed ID: 6450505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen.
    Becher R; Miller AA; Höffken K; Gerhold U; Hirche H; Schmidt CG
    Cancer; 1989 May; 63(10):1938-43. PubMed ID: 2522811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.
    Mangioni C; Franceschi S; La Vecchia C; D'Incalci M
    Gynecol Oncol; 1981 Dec; 12(3):314-8. PubMed ID: 6458544
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.